Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bauer

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
British Journal of Clinical Pharmacology|October 21, 2024
Single-dose and steady-state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug-drug interaction studyAmelie Leutzendorff, Valentin Al Jalali, Martin Bauer, et al.
Molecular Pharmaceutics|September 6, 2018
Effect of Rifampicin on the Distribution of [<sup>11</sup>C]Erlotinib to the Liver, a Translational PET Study in Humans and in MiceMartin Bauer, Alexander Traxl, Akihiro Matsuda, et al.
Artificial Organs|November 25, 2010
The role of phospho-adenosine monophosphate-activated protein kinase and vascular endothelial growth factor in a model of chronic heart failureFlorian Heidrich, Samuel Sossalla, Hanna Schotola, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2019
Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate <sup>11</sup>C-Metoclopramide Assessed with PET Imaging in HumansNicolas Tournier, Martin Bauer, Verena Pichler, et al.
Epilepsia|May 9, 2007
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamilOliver Langer, Martin Bauer, Alexander Hammers, et al.
Frontiers in Immunology|April 2, 2021
Activation of Neutrophil Granulocytes by Platelet-Activating Factor Is Impaired During Experimental SepsisStefan Hug, Stefan Bernhard, Alexander Elias Paul Stratmann, et al.
Fluids and Barriers of the CNS|October 28, 2024
[<sup>11</sup>C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patientsMyriam El Biali, Louise Breuil, Matthias Jackwerth, et al.
Clinical and Translational Science|May 3, 2024
St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrierMyriam El Biali, Michael Wölfl-Duchek, Matthias Jackwerth, et al.
European Journal of Clinical Pharmacology|May 10, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9Markus Zeitlinger, Martin Bauer, Roman Reindl-Schwaighofer, et al.
Clinical Pharmacology and Therapeutics|September 24, 2017
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission TomographyMartin Bauer, Akihiro Matsuda, Beatrix Wulkersdorfer, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
British Journal of Clinical Pharmacology|October 21, 2024
Single-dose and steady-state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug-drug interaction studyAmelie Leutzendorff, Valentin Al Jalali, Martin Bauer, et al.
Molecular Pharmaceutics|September 6, 2018
Effect of Rifampicin on the Distribution of [<sup>11</sup>C]Erlotinib to the Liver, a Translational PET Study in Humans and in MiceMartin Bauer, Alexander Traxl, Akihiro Matsuda, et al.
Artificial Organs|November 25, 2010
The role of phospho-adenosine monophosphate-activated protein kinase and vascular endothelial growth factor in a model of chronic heart failureFlorian Heidrich, Samuel Sossalla, Hanna Schotola, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2019
Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate <sup>11</sup>C-Metoclopramide Assessed with PET Imaging in HumansNicolas Tournier, Martin Bauer, Verena Pichler, et al.
Epilepsia|May 9, 2007
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamilOliver Langer, Martin Bauer, Alexander Hammers, et al.
Frontiers in Immunology|April 2, 2021
Activation of Neutrophil Granulocytes by Platelet-Activating Factor Is Impaired During Experimental SepsisStefan Hug, Stefan Bernhard, Alexander Elias Paul Stratmann, et al.
Fluids and Barriers of the CNS|October 28, 2024
[<sup>11</sup>C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patientsMyriam El Biali, Louise Breuil, Matthias Jackwerth, et al.
Clinical and Translational Science|May 3, 2024
St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrierMyriam El Biali, Michael Wölfl-Duchek, Matthias Jackwerth, et al.
European Journal of Clinical Pharmacology|May 10, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9Markus Zeitlinger, Martin Bauer, Roman Reindl-Schwaighofer, et al.
Clinical Pharmacology and Therapeutics|September 24, 2017
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission TomographyMartin Bauer, Akihiro Matsuda, Beatrix Wulkersdorfer, et al.
Pageof 21